Novartis declares cash offer for NeuTec Pharma wholly unconditional

17-Jul-2006

Novartis announced that it has acquired or received valid acceptances for 75.4% of the outstanding shares in NeuTec Pharma plc and has declared its offer for the UK biopharmaceutical company unconditional in all respects. This will allow for the delisting of NeuTec's shares and completing the acquisition.

The NeuTec Board of Directors unanimously recommended a cash offer announced on June 7 for Novartis to acquire the company for GBP 10.50 per share, which values NeuTec at approximately GBP 305 million (USD 569 million).

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...